The European Patent Organization, EPO, has announced its intention to approve (Intention to Grant) a patent for Iconovo’s inhaler platform, ICOres.
Iconovo has previously had three approved Swedish patents for ICOres, but this is the first in Europe.
The patent describes the technology used in several of Iconovo’s customer projects. “This is very good news and a confirmation that our technology is unique and innovative. An approved patent in Europe is extremely important because Europe is the largest market for ICOres. In this way, our offering has become even stronger, ”says Orest Lastow, CEO.